Introduction
Leflunomide is a disease-modifying anti-rheumatic drug 
Case Report
A 31-year-old woman presented to the emergency room complaining of a painful, itchy maculopapular rash distributed over her entire body and oral cavity pain for the last two days.
She was diagnosed with seropositive rheumatoid arthritis four years previously, and she had been followed up as an outpatient. When rheumatoid arthritis was first diagnosed, she was treated with methotrexate monotherapy until she got pregnant. After giving birth, she was treated with pre- After two days, the vesicles and macules changed to bullae that spread rapidly to the rest of her body (abdomen, back, extremities, palms, and soles) and covered 64% of her total body surface area. Eventually, the patient was diagnosed with toxic epidermal necrolysis. The patient was treated with methylprednisolone 24 mg/day and colestyramine 24 mg/day for leflunomide wash-out and immunoglobulin, 1 g/kg total dose over three days.
After five days, the lesions coalesced into large areas of epidermal detachment, and Nikolsky's sign was present 
Summary
Here we describe a first case of toxic epidermal necrolysis induced by leflunomide in a patient with rheumatoid arthritis in Korea. Clinicians have to be aware of toxic epidermal necrolysis induced by leflunomide and should carefully monitor presence of skin lesion.
